文献速递前列腺增生与排尿功能障碍

钬激光前列腺剜除术十年多中心真实世界实践关键分析

Critical analysis of a multicentric experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia: outcomes and complications of 10 years of routine clinical practice.
PubMed 文献 · BJU Int · 2020-02-27

该研究回顾性分析三家医院十年内接受钬激光前列腺剜除术(HoLEP)的963例良性前列腺增生(BPH)患者,评估围手术期结局及影响因素。结果显示手术时间平均77分钟,住院和导尿时间分别为4天和1.3天,中转开放或经尿道电切率3.7%,血红蛋白和血细胞比容显著下降但抗凝/抗血小板亚组无差异,结论认为HoLEP适用于真实世界BPH患者。

要点

  • HoLEP可用于抗凝/抗血小板治疗、合并膀胱结石或前列腺≥100 mL的BPH患者。
  • 平均手术时间77分钟,住院4天,导尿1.3天,中转手术率3.7%。
  • 前列腺≥100 mL或同期处理膀胱结石延长手术时间,但不影响安全性和有效性。

核心结论

  • HoLEP适用于真实世界的BPH患者,无论是否正在接受抗凝/抗血小板治疗、合并膀胱结石或前列腺≥100 mL。

研究设计与样本

  • 回顾性分析三家医院十年常规实践中接受HoLEP治疗的BPH患者,共纳入963例,年龄48-91岁,平均前列腺体积91(范围35-247)mL。

主要发现

  • 平均(标准差)手术时间为77(29)分钟,住院时间和导尿时间分别为4(2)天和1.3(2)天。
  • 56例(5.6%)同期行膀胱结石取出,36例(3.7%)因术中并发症中转开放前列腺切除术或经尿道前列腺电切术。
  • 患者血红蛋白和血细胞比容显著下降,但抗凝/抗血小板治疗组与未治疗组、前列腺≥100 mL与<100 mL组之间无差异。
  • 同期取出膀胱结石和前列腺≥100 mL导致手术时间延长,但未影响安全性和有效性结局。

临床怎么用

  • HoLEP可考虑用于正在接受抗凝/抗血小板治疗、合并膀胱结石或前列腺体积≥100 mL的BPH患者。
  • 对于前列腺≥100 mL或需同期处理膀胱结石的患者,应预期手术时间延长,但安全性及有效性结局不受影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the perioperative outcomes of holmium laser enucleation of the prostate (HoLEP) in real-life practice and investigate the factors influencing the safety and effectiveness of the technique. PATIENTS AND METHODS: Critical analysis of patients with benign prostate hyperplasia (BPH) treated with HoLEP over 10 years of routine practice in three hospitals. Analysed variables included: preoperative characteristics (prostate size, active antiplatelet/anticoagulant therapy, blood parameters. prostate-specific antigen (PSA) level, maximum urinary flow rate [Qmax ], and International Prostate Symptom Score [IPSS]), intraoperative variables (operation time, concomitant removal of bladder calculi, and complications), early postoperative outcomes (change in blood parameters, catheterisation time, and hospital stay), and 12-month follow-up outcomes (change in IPSS, PSA level, and Qmax ). RESULTS: The analysis included 963 patients, aged 48-91 years, with a mean (range) prostate size of 91 (35-247) mL. The mean (sd) operation time was 77 (29) min, and the hospital stay and catheterisation time were 4 (2) and 1.3 (2) days, respectively. In all, 56 patients (5.6%) required concomitant removal of bladder calculi and 36 (3.7%) were converted to open prostatectomy or transurethral resection of the prostate due to intraoperative complications. Patients had a significant decrease in haemoglobin and haematocrit, but no differences were seen between patients with and without anticoagulant/antiplatelet therapy and those with prostates ≥ and <100 mL. The concomitant removal of bladder calculi and having a prostate ≥100 mL resulted in a longer operation time, but did not influence the safety and effectiveness outcomes. CONCLUSIONS: HoLEP is suitable for real-life patients with BPH, irrespective of the presence of active treatment with anticoagulant/antiplatelet, bladder lithiasis or a prostate ≥100 mL.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Romero-Otero J, García-Gómez B, García-González L, et al. Critical analysis of a multicentric experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia: outcomes and complications of 10 years of routine clinical practice. BJU Int. 2020. PMID: 32020749. doi:10.1111/bju.15028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。